Investor Centre

Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
Stat background
0.72 GBX Volume: 26,775 Market Capitalisation (m) £3.08

Corporate Presentation

10 - May - 2024
Current corporate presentation

Acquisition, Fundraising and Change of Name

19 - March - 2024
Evgen announces the acquisition of Chronos Therapeutics, placing and subscription offer and company name change.

Investor Meet Presentation – Proposed Acquisition of Chronos Therapeutics Ltd, Placing and Accompanying Retail Offer

21 - March - 2024
CEO Dr Huw Jones, CBO Dr Helen Kuhlman and new CFO Toni Haenninen discuss Evgen's proposed acquisition of Chronos Therapeutics Ltd.
Company Analyst
Cavendish Chris Donnellan

Major Shareholder

Current ShareholderNumber of sharesPercentage holding
J. R. Kight33,100,0007.75%
Rathbones Investment Management Ltd25,789,2466.03%
Octopus Investments21,875,0005.12%
Vulpes Investment Management Pte Ltd20,554,1914.81%
First Equity Limited20,000,0004.68%
Seneca Partners Limited16,301,4563.81%
The number of ordinary shares in issue is 427,346,895 all of which are in public hands. The Company does not hold any shares in Treasury.
Last updated 25 April 2024